Login / Signup

Ptbp1 knockdown failed to induce astrocytes to neurons in vivo.

Guixiang YangZixiang YanXiaoqing WuMeng ZhangChunlong XuLinyu ShiHui YangKailun Fang
Published in: Gene therapy (2023)
The conversion of non-neuronal cells to neurons is a promising potential strategy for the treatment of neurodegenerative diseases. Recent studies have reported that shRNA-, CasRx-, or ASO-mediated Ptbp1 suppression could reprogram resident astrocytes to neurons. However, some groups have disputed the interpretation of the data underlying the reported neuron conversion events. These controversies surrounding neuron conversion may be due to differences in the astrocyte fate-mapping systems. Here, we suppressed Ptbp1 using Cas13X and labelled astrocytes with an HA tag fused to Cas13X (Cas13X-NLS-HA). We found no astrocyte-to-neuron conversion in the mouse striatum via the HA-tagged labelling system compared with the GFAP-driven tdTomato labelling system (AAV-GFAP::tdTomato-WPRE) used in previous studies. Our findings indicate that Cas13X-mediated Ptbp1 knockdown failed to induce neuron conversion in vivo.
Keyphrases
  • crispr cas
  • genome editing
  • spinal cord
  • case control
  • cell death
  • big data
  • risk assessment
  • gene therapy
  • oxidative stress
  • signaling pathway
  • artificial intelligence
  • brain injury
  • human health
  • subarachnoid hemorrhage